CD1-HM119-100μg / 询价
CD1-HM119-500μg / 询价
CD1-HM119-500μgx2 / 询价
- 客服电话
- 技术支持
Human CD19 Protein
Recombinant Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus It contains Pro20-Lys291 [Accession | P15391-1].
The protein has a predicted MW of 34.7 kDa. Due to glycosylation, the protein migrates to 50-60 KDa based on Bis-Tris PAGE result.
>95% as determined by Bis-Tris PAGE
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human CD19 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Immobilized Human CD19, His Tag at 2 μg/ml (100 μl/Well) on the plate. Dose response curve for Coltuximab, hFc Tag with the EC50 of 5.3 ng/ml determined by ELISA (QC Test).
Immobilized Human CD19, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for FMC63, mFc Tag with the EC50 of 10.0 ng/ml determined by ELISA (QC Test).
Immobilized Human CD19, His Tag at 1 μg/ml (100 μl/Well) on the plate. Dose response curve for Inebilizumab, hFc Tag with the EC50 of 11.5 ng/ml determined by ELISA.
Immobilized Human CD19, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Denintuzumab, hFc Tag with the EC50 of 2.1 ng/ml determined by ELISA.
CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses. Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca2 stores.
CD19; B4; CVID3; Leu-12; MGC12802
(1) Maude S L, Teachey D T, Porter D L, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia[J]. Blood, 2015, 125(26):4017-23.
